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overuse and underuse of thromboprophylaxis, thereby con-
ﬁrming and extending previously published data [7–9].
In conclusion, decision-making for thromboprophylaxis in
current clinical practice seems too random in acutely ill medical
patients. Our results point out to the need for developing and
implementing explicit evidenced-based criteria and to stan-
dardize the indications for prevention of venous thrombo-
embolism in these patients, as recently reminded [10]. Because
the present heterogeneity and inadequacy of practice is
probably large because of the lack of clear, immediately
applicable guidelines, the simple score assessed in the present
study might represent a promising step toward this necessary
standardization of practice.
Acknowledgements
Patients included in the database were initially recruited by
J. Do¨rﬄer (Bern), U. Hess (St. Gall), W. A. Wuillemin
(Lucerne), D. Hayoz (Lausanne), A. Gallino (Bellinzona),
E. B. Bachli (Zurich), C. R. Canova (Chur), J. Isenegger (Bern)
and H. Bounameaux (Geneva), all in Switzerland (for details,
see reference no. 2). Unrestricted support was provided by
Sanoﬁ-Synthelabo (Switzerland) for the present analysis.
References
1 Chmelik P, Chopard P, Bounameaux H. An evaluation of thrombo-
embolism prophylaxis in acutely ill medical patients. Swiss Med Wkly
2002; 132: 513–6.
2 Chopard P, Do¨rﬄer-Melly J, Hess U, Wuillemin WA, Hayoz D,
Gallino A, Ba¨chli EB, Canova CR, Isenegger J, Rubino R, Bouna-
meaux H. Venous thromboembolism prophylaxis in acutely ill medical
patients: deﬁnite need for improvement. J InternMed 2005; 257: 352–7.
3 Lutz L, Haas S, Hach-Wunderle V, Betzl G, Jamartz H. Venous
thromboembolism in internal medicine: risk assessment and pharma-
ceutical prophylaxis. Med Welt 2002; 53: 231–4.
4 Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell
CW, Ray JG. Prevention of venous thromboembolism. Prevention of
Venous Thromboembolism: The Seventh ACCP Conference on
Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 338S–
400S.
5 Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Jan-
bon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG,Weisslinger
N. A comparison of enoxaparin with placebo for the prevention of
venous thromboembolism in acutely ill medical patients. Prophylaxis
in Medical Patients with Enoxaparin Study Group. N Engl J Med
1999, 341: 793–800.
6 Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT,
Goldhaber SZ for the PREVENT Medical Thromboprophylaxis
Study Group. Randomized, placebo-controlled trial of dalteparin for
the prevention of venous thromboembolism in acutely ill medical pa-
tients. Circulation 2004; 110: 874–9.
7 Aujesky D, Guignard E, Pannatier A, Cornuz J. Pharmacological
thromboembolic prophylaxis in a medical ward. J Gen Intern Med
2002; 17: 788–91.
8 Rahim SA, Panju A, Pai M, Ginsberg J. Venous thromboembolism
prophylaxis in medical inpatients: a retrospective chart review.Thromb
Res 2003; 111: 215–9.
9 Fiessinger JN, Chatelier G. Eﬀect of prescription and monitoring
recommendations on prescription of low-molecular weight
heparins. Presse med 1996; 25: 1777–80.
10 Bergmann JF, Kher A. Venous thromboembolism in the medically ill
patient: a call to action. Int J Clin Pract 2005; 59: 555–61.
Risk of arterial thrombosis in carriers of familial thrombophilia
C. Y . VOSSEN* and F . R . ROSENDAAL* ON BEHA LF OF THE EPCOT STUDY G ROUP
Departments of *Clinical Epidemiology and Haematology, Leiden University Medical Center, Leiden, the Netherlands
To cite this article: Vossen CY, Rosendaal FR on behalf of the EPCOT Study Group. Risk of arterial thrombosis in carriers of familial thrombophilia.
J Thromb Haemost 2006; 4: 916–8.
Factor (F) V Leiden, the prothrombin G20210Amutation and
inherited deﬁciencies in antithrombin, protein C, and protein S
are established risk factors for venous thrombosis [1], but their
impact on arterial disease is less evident because of a paucity of
large studies [2–6]. Results appear contradictory [7–11], which
may be explained by the presence or absence of additional
cardiovascular risk factors. The risk of arterial disease may
stand out more in thrombophilic families, in which multiple
risk factors interact in increasing the risk of thrombosis [12,13].
In 1993, the European Prospective Cohort on Thrombo-
philia (EPCOT) study was initiated. The primary aim of this
study was to determine the risk of venous thrombosis in
thrombophilic families. In addition, information was gathered
on arterial events [e.g. myocardial infarction (MI), ischemic
stroke (IS) and transient ischemic attacks (TIA)]. The design of
the study has been described in detail previously [14,15]. All
participants were enrolled betweenMarch 1994 and September
1997. The inherited defects studied were the FV Leiden
mutation, deﬁciencies of protein C, protein S or antithrombin,
or a combination of these defects. During follow-up, we
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determined the presence of the prothrombin G20210A muta-
tion as an additional defect in thrombophilic individuals. We
calculated the absolute risk (incidence) of arterial events before
study entry in participants older than 20 years at study
inclusion. The incidence was calculated by dividing the number
of arterial events by the total of observation-years, i.e. the
number of years between the age of 20 and inclusion in the
study or a ﬁrst MI or IS, whichever occurred ﬁrst. TIAs were
not taken into account, as the diagnosis of a TIA is more
difﬁcult. The 95% conﬁdence intervals (95% CI) were calcu-
lated according to the Poisson distribution for the number of
events [16]. Hazard ratios as an estimation of the relative risk
were calculated by Cox-regression for men and women
separately. To minimize selection bias, we included in this
analysis only individuals who were screened for thrombophilia
because of a personal or family history of venous thrombosis
and not for other reasons such as arterial thrombosis or family
planning. To avoid any inﬂuence from the use of (long-term)
anticoagulation on which we had no detailed information
before study entry, we focused on participants who did not
experience venous thrombotic events and we excluded all
asymptomatic individuals on long-term anticoagulation during
follow-up. Because of a small number of arterial events during
follow-up (n ¼ 6) in thrombophilic individuals without a
history of venous or arterial thrombosis and anticoagulant
treatment, we did not calculate the incidence of arterial events
during prospective follow-up.
In total, 622 individuals with thrombophilia (60 probands
and 562 relatives) and 1125 controls (878 partners and 247
friends) fulﬁlled the eligibility criteria. The age at inclusion was
43 years (range 21–91) in thrombophilic individuals and
43 years (range 21–87) in controls. Table 1 shows the incidence
per 1000 person years of a ﬁrstMI and IS before study entry for
the thrombophilic individuals and controls. The mean age at
the ﬁrst MI or IS was 58 years (range 41–77) in controls and
48 years (range 24–67) in thrombophilic individuals (Table 1).
The risk of developing a ﬁrst MI or IS associated with
thrombophilia was increased 12-fold in men (relative risk 12.1;
95% CI 4.1–35.7) and sevenfold in women (relative risk 7.1;
95% CI 0.8–61.2). The relative risk was 8.8 (95% CI 2.9–27.0)
in men and 4.5 (95%CI 0.5–43.5) in women when we excluded
the probands, i.e. the ﬁrst of a family in whom thrombophilia
was detected. The incidence ranged from 1.4 per 1000 person
years in those with combined defects to 2.1 per 1000 person
years in FV Leiden carriers (Table 1). MIs were more common
than ISs in individuals with FV Leiden, whereas no MIs were
present among individuals with antithrombin deﬁciency
(Table 1).
Our results show an increased risk of arterial thrombosis in
individuals with inherited thrombophilia. Unfortunately, this is
a retrospective analysis and we lack information on additional
cardiovascular risk factors such as smoking and hypertension
to perform further risk stratiﬁcation. The risk was lower than
the risk found for venous thrombosis before study entry (4.4
per 1000 person years) [14]. The incidence of MI or IS in the
controls was lower than the incidence in controls in a recent
retrospective study (0.5 per 1000 for MI and 0.2 per 1000 for
IS) [17]. However, they also included relatives from probands
with premature atherosclerosis [17]. On the other hand, the
incidences in our study could be underestimated as we focussed
on participants who did not experience venous thrombotic
events and did not use long-term anticoagulation treatment,
who might have had the highest risk of developing arterial
events. Incidences could be also be overestimated because we
did not have information on whether the arterial events were
objectively conﬁrmed and underestimated because we did not
include those with fatal arterial events. Nevertheless, it is
unlikely that any of these limitations would explain a difference
between thrombophilic individuals and controls, and therefore,
these ﬁndings indicate that familial coagulation defects do
affect the risk of arterial disease and that venous and arterial
events share common risk factors.
Table 1 Number and incidence per 1000 person years of a ﬁrstMI or IS in thrombophilic individuals and controls without a VT history before inclusion in
the EPCOT study
Total
(n)
Total
events (n)
MI
(n)
IS
(n)
Mean age at
event (range)
Incidence MI/IS per 1000
person years (95% CI)
Controls 1125 5 5 0 58 (41–77) 0.2 (0.1–0.4)
Men 588 4 4 0 58 (41–77) 0.3 (0.1–0.7)
Women 537 1 1 0 57 0.1 (0.0–0.4)
Thrombophilics 622 24 15 9 48 (24–67) 1.7 (1.1–2.6)
Men 220 19 12 7 48 (29–65) 3.8 (2.3–6.0)
Women 402 5 3 2 45 (24–67) 0.6 (0.2–1.3)
PC 150 5 2 3 48 (30–65) 1.5 (0.5–3.5)
PS 111 4 3 1 48 (41–58) 1.8 (0.5–4.5)
AT 92 3 0 3 39 (29–49) 1.5 (0.3–4.3)
FVL 208 10 9 1 52 (43–67) 2.1 (1.0–3.9)
>1 defect 61* 2 1 1 38 (24–53) 1.4 (0.2–5.1)
MI, Myocardial infarction; IS, ischemic stroke, CI, conﬁdence interval; PC, protein C deﬁciency; PS, protein S deﬁciency; AT, antithrombin
deﬁciency; FVL, factor V Leiden.
*13 with PC-FVL, one with PC-PS, 15 with PS-FVL, four with AT-FVL, 15 with PT20210A-FVL, nine with PC-PT20210A, three with PS-
PT20210A and one with AT-PT20210A.
This person had PS deﬁciency and FVL.
This person had AT deﬁciency and FVL.
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In the traditional view of blood coagulation, vascular injury
leads to the exposure of extravascular membrane-bound tissue
factor (TF) to the blood stream thereby initiating blood clot
formation. Essential in this model of hemostasis is that TF is
normally not in contact with blood as it resides in the
adventitial lining of blood vessels. However, a soluble TF
variant, which is derived by alternatively splicing of the TF
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